Global Neuroendocrine Tumors (NET) Market Report 2017: Novartis Leads Industry Sponsors with the Highest Number of Clinical Trials for NETs, Followed by Ipsen and Pfizer
DUBLIN, Feb. 15, 2018 /PRNewswire/ --
The "Market Spotlight: Neuroendocrine tumors (NET)" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This Market Spotlight report covers the Neuroendocrine Tumors market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
-- The author estimates that in 2016, there were approximately 450,300
incident cases of neuroendocrine tumors (NETs) worldwide, and forecasts
that number to increase to 543,800 incident cases by 2025.
-- Worldwide, the majority of NETs were malignant carcinoid tumors or
neuroendocrine carcinomas. The approved drugs in the NETs target
somatostatin receptors, tyrosine hydroxylase, mammalian target of
rapamycin/mTORC, FMS-like tyrosine kinase 3, KIT/c-KIT, platelet-derived
growth factor receptor, VEGF receptor, and ganglioside GD2. These drugs
are administered via the oral, intravenous, and subcutaneous routes,
however, one product is available in intramuscular formulation.
-- Two therapies are currently in NDA/BLA phase for NETs. Therapies in the
pipeline for NETs focus on a wide variety of targets. The majority of
pipeline drugs in development are administered intravenously, with a few
drugs being tested in oral, subcutaneous, intranasal, intramuscular and
intratumoral formulations.
-- High-impact upcoming events in the NETs space include topline Phase III
trial results for sulfatinib, and estimated PDUFAs for Lutathera and
Azedra.
-- There were only five licensing and asset acquisition activities
involving NETs drugs during 2012-17. The $115m exclusive licensing
agreement (in November 2017) between Nanocarrier and VBL therapeutics,
for the development, commercialization, and supply of VB-111
(ofranergene obadenovec) in Japan, was the only deal with disclosed deal
value during the period.
-- Somatuline Autogel's composition patent, and Sutent's method of use
patent are set to expire in 2020 and 2021, respectively, which will open
the door to generic entry.
-- Afinitor sales ranked highest in the NETs space during 2012-16, however,
its sales are forecasted to plummet during 2017-22 to reach $305m by
2021.
-- The clinical trials distribution across Phase I-IV indicates that the
majority of trials for NETs have been in early and mid-phases of
development, with 79% of trials in Phase I-II, and only 21% in Phase
III-IV.
-- The US has a substantial lead in the number of NETs clinical trials
globally. The UK leads the major EU markets. Clinical trial activity in
the NETs space is dominated by completed trials. Ipsen has the highest
number of completed clinical trials for NETs, with eight completed
trials, followed by Novartis and Pfizer with five completed trials each.
-- Novartis leads industry sponsors with the highest number of clinical
trials for NETs, followed by Ipsen and Pfizer.
Key Topics Covered:
KEY TAKEAWAYS
DISEASE BACKGROUND
Neuroendocrine Tumors Subtypes
TREATMENT
Surgery
Hepatic artery embolization
Somatostatin analogues
Interferon-alpha (IFN-alpha)
Chemotherapy
Radiation therapy
Targeted therapy
Palliative care
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
KEY UPCOMING EVENTS
LICENSING AND ASSET ACQUISITION DEALS
Confirming Rumors, Novartis Buys AAA To Boost Oncology Business
Will AAA's Nuclear Med Offerings Turn M&A Buzz into A Deal?
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Recent Events
BIBLIOGRAPHY
Prescription Information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/research/hr7n2d/global?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
